Overview

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
0
Participant gender:
Female
Summary
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Diphosphonates
Criteria
Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma

- At least one bone metastasis